Post Exposure Prophylaxis News and Research

RSS

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.

3 Jun 2021

Reducing COVID-19 burden with monoclonal antibodies and vaccination

Researchers in the United States, the UK and France have shown that using antiviral monoclonal antibodies in combination with vaccination can be expected to suppress the transmission of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) and reduce the burden of coronavirus disease 2019 (COVID-19) more than vaccination alone.

26 May 2021

New guidelines outline key new actions to improve delivery of HIV testing, treatment and care

These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living with HIV who are being treated for tuberculosis.

23 Mar 2021

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

22 Feb 2021

Pediatric trial results show rabies treatment is safe and effective in children

A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under.

10 Feb 2021

Effective vaccine strategies for New South Wales Australia under different vaccine supply

Researchers say mass immunization will terminate the disease, or immunizing 66% of the population with a 90% efficacy vaccine will achieve herd immunity.

21 Dec 2020

Hydroxychloroquine found ineffective as post-exposure SARS-CoV-2 prophylaxis

Now, a study on the utility of hydroxychloroquine as prophylaxis against COVID-19, has been released in the latest issue of Annals of Internal Medicine.

10 Dec 2020

Chloroquine/hydroxychloroquine could treat COVID-19 infection

The recent serious outbreak of Covid19 has affected (November 13, 2020) 53,796,098 people worldwide, resulting in 37,555,669 recovered, 1,310,250 deaths, and a large number of open cases.

1 Dec 2020

Mathematical modeling study offers new insights into optimal timing of antiviral therapies against COVID-19

A new mathematical modeling study by Ashish Goyal and colleagues, informed by data collected from 25 patients hospitalized with COVID-19 in 4 different countries, offers some important new insights into the optimal timing of 4 different antiviral therapies to combat the disease.

23 Oct 2020

Countries should step-up leprosy prevention initiatives to accelerate decline in new cases

New cases of leprosy are decreasing, but not at the anticipated rate. In order to accelerate the annual decline, countries should screen contacts and treat eligible contacts with single-dose rifampicin, as recommended by the World Health Organization in its guidelines.

8 Sep 2020

Clinical trials of hydroxychloroquine in COVID-19 outpatients reported as safe

According to new research, the use of hydroxychloroquine among outpatients in clinical trials, without high-risk factors for cardiac arrhythmia, is safe.

27 Jul 2020

Researchers isolate potent SARS-CoV-2 neutralizing antibodies

An important line of defense in the fight against the new coronavirus SARS-CoV-2 is the formation of neutralizing antibodies.

8 Jul 2020

Scientists launch clinical trial to test the efficacy of HIV drug against COVID-19 infection

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug used for HIV treatment and prevention may work to prevent COVID-19 infection.

28 Apr 2020

New clinical trial to test two drugs for prophylactic treatment of COVID-19 contact persons

With the stepwise easing of measures in Switzerland, it is pivotal to monitor for any new COVID-19 outbreaks and to contain them in a timely and effective manner.

23 Apr 2020

New prophylactic and therapeutic avenues to fight against rabies

Rabies is still responsible for approximately 60,000 human deaths per year mostly in Asia and Africa and affects especially underserved people.

11 Feb 2020

Timing is key: preventing infant SHIV infection by PEP

Researchers tested methods to prevent development of SHIV, an infection similar to HIV, in infant macaque monkeys.

9 Jan 2020

Homeless rape victims are not seeking post-sexual assault medical care

Nearly three-fourths of young adults experiencing homelessness who are raped do not seek post-sexual assault medical care, missing an opportunity to greatly reduce their risk of contracting HIV, according to a survey led by The University of Texas Health Science Center at Houston.

16 Dec 2019

NIH Statement for World AIDS Day outlines efforts to end the HIV epidemic

With World AIDS Day on 1st December, we are reminded by the NIH of the work that needs to be done to end the HIV Epidemic.

28 Nov 2019

HIV diagnosis falls to a record low in NYC, finds report

Reporting of new cases of HIV started in 2001 and since then there has been a steady rise and stability of numbers. In 2018 for the first time in nearly two decades, researchers have reported number of new cases to be below 2,000 over the year. This is a record 67 percent decline in the numbers since 2001, says the report. Further the decline in the numbers has been seen in nearly all age groups between 2017 and 2018.

25 Nov 2019

New California law may expand use of HIV prevention drugs, with caveats

Kellen Willhite was 24 when he learned he'd been exposed to HIV. What followed was, as he describes it, a second trauma: trying to obtain the drugs that could save him before it was too late.

20 Nov 2019